Baird analyst David Rescott lowered the firm’s price target on Edwards Lifesciences (EW) to $87 from $88 and keeps a Neutral rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees “several potential paths to improved” share performance for the group in 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences Completes Key Study on SAPIEN XT THV
- Edwards Lifesciences price target raised to $101 from $96 at Citi
- Edwards Lifesciences price target raised to $103 from $99 at Barclays
- Edwards Lifesciences price target raised to $100 from $95 at RBC Capital
- Edwards Lifesciences price target raised to $92 from $90 at Truist